PRESS RELEASES

Date Title View
Toggle Summary Chimerix to Announce Third Quarter 2016 Financial Results on November 7, 2016
DURHAM, N.C. , Oct. 31, 2016 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that it will host a live conference call and audio webcast on Monday, November 7, 2016 at 8:30 a.m.
View HTML
Toggle Summary Chimerix Announces Presentation at IDWeek™ of Detailed 24-Week Results from AdVise Trial of Brincidofovir for the Treatment of Adenovirus Infection in Allogeneic Hematopoietic Cell Transplant Recipients
- Results Show Early Virologic Response Associated with Better Overall Survival - DURHAM, N.C. , Oct. 27, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals in areas of high unmet medical need, today announced the presentation of detailed
View HTML
Toggle Summary Chimerix to Present at the Morgan Stanley Global Healthcare Conference
DURHAM, N.C. , Sept. 06, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that M. Michelle Berrey , M.D., M.P.H, Chief Executive Officer of Chimerix , will present at the Morgan Stanley Global
View HTML
Toggle Summary Chimerix Announces Second Quarter 2016 Financial Results
- European Commission Granted Orphan Drug Designation for Brincidofovir for the Treatment of Adenovirus - - Conference Call at 8:30 a.m. ET Today - DURHAM, N.C. , Aug. 08, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet
View HTML
Toggle Summary Chimerix to Announce Second Quarter 2016 Financial Results on August 8, 2016
DURHAM, N.C. , Aug. 01, 2016 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel antivirals in areas of high unmet medical need, today announced that it will host a live conference call and audio webcast on Monday, August 8, 2016 at 8:30 a.m.
View HTML
Toggle Summary Chimerix to Participate in Panel on North Carolina's Role in Biodefense Preparation at Medical, Biomedical and Biodefense Symposium
DURHAM, N.C. , June 07, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals in areas of high unmet medical need, today announced that M. Michelle Berrey , M.D., M.P.H., President and Chief Executive Officer of Chimerix , will participate in a
View HTML
Toggle Summary Chimerix Announces Top-Line Interim AdVise Data and First Quarter 2016 Financial Results
- Maintains strong financial position with $314.5 million in capital at quarter end - - Company to hold conference call at 8:30am ET today - DURHAM, N.C. , May 09, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical
View HTML
Toggle Summary Chimerix to Announce First Quarter 2016 Financial Results on May 9, 2016
DURHAM, N.C. , May 03, 2016 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that it will host a live conference call and audio webcast on Monday, May 9, 2016 at 8:30 a.m.
View HTML
Toggle Summary Chimerix to Present at the Barclays Global Healthcare Conference
DURHAM, N.C. , March 09, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral antivirals to address unmet medical needs, today announced that Linda M. Richardson , Chief Commercial Officer of Chimerix , will present at the Barclays Global Healthcare
View HTML
Toggle Summary Chimerix to Present at Cowen and Company 36th Annual Health Care Conference
DURHAM, N.C. , March 01, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel, oral antivirals to address unmet medical needs, today announced that M. Michelle Berrey , M.D., M.P.H., President and Chief Executive Officer of Chimerix , will present at the 36
View HTML